rs749272546
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_018368.4(LMBRD1):c.1056del(p.Asn353IlefsTer18) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00061 in 1,602,780 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.00059 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00061 ( 0 hom. )
Consequence
LMBRD1
NM_018368.4 frameshift
NM_018368.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 0.576
Genes affected
LMBRD1 (HGNC:23038): (LMBR1 domain containing 1) This gene encodes a lysosomal membrane protein that may be involved in the transport and metabolism of cobalamin. This protein also interacts with the large form of the hepatitis delta antigen and may be required for the nucleocytoplasmic shuttling of the hepatitis delta virus. Mutations in this gene are associated with the vitamin B12 metabolism disorder termed, homocystinuria-megaloblastic anemia complementation type F.[provided by RefSeq, Oct 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
?
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
?
Very rare variant in population databases, with high coverage;
PP5
?
Variant 6-69701469-TC-T is Pathogenic according to our data. Variant chr6-69701469-TC-T is described in ClinVar as [Pathogenic]. Clinvar id is 225048.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr6-69701469-TC-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
LMBRD1 | NM_018368.4 | c.1056del | p.Asn353IlefsTer18 | frameshift_variant | 11/16 | ENST00000649934.3 | |
LMBRD1 | NM_001363722.2 | c.837del | p.Asn280IlefsTer18 | frameshift_variant | 11/16 | ||
LMBRD1 | NM_001367271.1 | c.837del | p.Asn280IlefsTer18 | frameshift_variant | 11/16 | ||
LMBRD1 | NM_001367272.1 | c.837del | p.Asn280IlefsTer18 | frameshift_variant | 11/16 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
LMBRD1 | ENST00000649934.3 | c.1056del | p.Asn353IlefsTer18 | frameshift_variant | 11/16 | NM_018368.4 | P2 |
Frequencies
GnomAD3 genomes ? AF: 0.000586 AC: 89AN: 151846Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
89
AN:
151846
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000463 AC: 115AN: 248514Hom.: 0 AF XY: 0.000513 AC XY: 69AN XY: 134444
GnomAD3 exomes
AF:
AC:
115
AN:
248514
Hom.:
AF XY:
AC XY:
69
AN XY:
134444
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000612 AC: 888AN: 1450816Hom.: 0 Cov.: 28 AF XY: 0.000634 AC XY: 458AN XY: 722398
GnomAD4 exome
AF:
AC:
888
AN:
1450816
Hom.:
Cov.:
28
AF XY:
AC XY:
458
AN XY:
722398
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.000586 AC: 89AN: 151964Hom.: 0 Cov.: 32 AF XY: 0.000565 AC XY: 42AN XY: 74278
GnomAD4 genome
?
AF:
AC:
89
AN:
151964
Hom.:
Cov.:
32
AF XY:
AC XY:
42
AN XY:
74278
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:11Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Methylmalonic aciduria and homocystinuria type cblF Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 24, 2017 | The LMBRD1 c.1056delG (p.Asn353IlefsTer18) variant results in a frameshift and is predicted to result in premature termination of the protein. Across a selection of the available literature, the p.Asn353IlefsTer18 variant has been identified in 11 individuals with disorders of intracellular cobalamin metabolism, including in a homozygous state in eight and in a compound heterozygous state in three (Rutsch et al. 2009; Miousse et al. 2011; Constantinou et al. 2016). An additional deceased proband with cobalamin deficiency was found to carry the p.Asn353IlefsTer18 variant and a second variant in the MTR gene, suggesting the possibility of digenic inheritance (Farwell Gonzalez et al. 2015). Phenotypic symptoms cover a wide range of symptoms including failure to thrive, neutropenia, developmental delay, stomatitis, megaloblastic anemia, and feeding difficulties; however, some patients may show asymptomatic long-term survival (Rutsch et al. 2009). Control data are unavailable for this variant, which is reported at a frequency of 0.00109 in the European American population of the Exome Sequencing Project. Transfection of immortalized fibroblasts from a compound heterozygous proband and a homozygous proband with wildtype LMBD1 was able to rescue the biochemical intracellular cobalamin pathway F (cblF) phenotype (Rutsch et al. 2009). Based on the collective evidence and the potential impact of frameshift variants, the p.Asn353IlefsTer18 variant is classified as pathogenic for disorders of intracellular cobalamin metabolism. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jan 29, 2024 | This sequence change creates a premature translational stop signal (p.Asn353Ilefs*18) in the LMBRD1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LMBRD1 are known to be pathogenic (PMID: 19136951, 21303734). This variant is present in population databases (rs749272546, gnomAD 0.09%), and has an allele count higher than expected for a pathogenic variant. This premature translational stop signal has been observed in individuals with Cobalamin F (cblF) deficiency (PMID: 19136951, 21303734, 23776111, 26997947). It is commonly reported in individuals of European ancestry (PMID: 19136951). ClinVar contains an entry for this variant (Variation ID: 225048). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 2009 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 27, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 15, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Sep 21, 2018 | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. This pathogenic variant has been previously reported in patients with methylmalonic aciduria and homocystinuria type cblF (MMAHCF) [PMID 19136951, 24664876, 23776111] - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Aug 30, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 21, 2021 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 24664876, 22065268, 19136951, 26997947, 23776111, 20127417, 21303734, 25533962, 31589614) - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 06, 2013 | - - |
Cobalamin C disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 08, 2022 | Variant summary: LMBRD1 c.1056delG (p.Asn353IlefsX18) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic in ClinVar and is associated with Methylmalonic aciduria & homocystinuria in HGMD. The variant allele was found at a frequency of 0.00046 in 248514 control chromosomes (gnomAD). This frequency is not higher than expected for a pathogenic variant in LMBRD1 causing Methylmalonic Acidemia With Homocystinuria (0.00046 vs 0.00079), allowing no conclusion about variant significance. c.1056delG has been reported in the literature in multiple homozygous and compound heterozygous individuals affected with Methylmalonic Acidemia With Homocystinuria and the variant segregated with disease (examples: Rutsch_2009 and Miousse_2011). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity (Rutsch_2009). Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Disorders of Intracellular Cobalamin Metabolism Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at